OraSure Technologies

FDA authorizes OraSure’s rapid test for Bundibugyo Ebola virus

The FDA on Tuesday granted Emergency Use Authorization to OraSure Technologies for its OraQuick Ebola 2.0 Rapid Antigen Test, a second-generation diagnostic capable of detecting the Bundibugyo virus driving the current Ebola epidemic in Central Africa.